Cencora, Inc. (COR) Stock
COR has an Alpha Score of 45 out of 100 (weak), computed on Nov 5, 2026 from 3 of 4 sub-scores. 5 members of Congress disclosed 8 trades in COR since 2019: 4 purchases and 4 sales, most recently Jared Moskowitz (sale, May 6, 2026). 7 of the hedge funds AlphaScala tracks reported COR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $386.73M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 24.6 and its net margin 0.8% (key statistics as of Nov 3, 2026).
What is COR's Alpha Score?
How it works →Alpha Score of 45 reflects weak overall profile with moderate momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Cencora, Inc. (COR)?
Most recent: Jared Moskowitz (sale, May 6, 2026); records start Jun 24, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Jared Moskowitz D-FL · House | 2026-05-06 | sale | $1k – $15k |
| Jared Moskowitz D-FL · House | 2026-03-31 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Jared Moskowitz D-FL · House | 2026-03-23 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $50k – $100k |
| Greg Landsman D-OH · House | 2025-03-27 | sale | $15k – $50k |
| Greg Landsman D-OH · House | 2024-05-29 | purchase | $15k – $50k |
| Donna Shalala D-FL · House | 2019-06-24 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all COR political trades →Which hedge funds own COR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.37M | $386.73M | +71% |
| Millennium Management Israel Englander | 950K | $268.97M | +154% |
| Point72 Steve Cohen | 605K | $171.13M | +53% |
| Marshall Wace | 342K | $96.83M | NEW |
| D.E. Shaw David Shaw | 58K | $16.36M | -39% |
| Bridgewater Associates Ray Dalio | 34K | $9.63M | +139% |
| Renaissance Technologies Jim Simons (founder) | 24K | $6.68M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Cencora, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Krikorian Lazarus | SVP & Chief Accounting Officer | SELL | 986 | $326K |
| Oct 1, 26 | Krikorian Lazarus | SVP & Chief Accounting Officer | SELL | 986 | $299K |
| Sep 16, 26 | Greenberg Lon R | Director | SELL | 1.3K | $411K |
| Sep 1, 26 | Krikorian Lazarus | SVP & Chief Accounting Officer | SELL | 985 | $321K |
| Aug 24, 26 | Campbell Elizabeth S | Executive Vice President | SELL | 11.3K | $3.7M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are COR's key statistics?
Key statistics as of Nov 3, 2026
How does COR's valuation compare with the Healthcare sector?
| Metric | COR | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 24.6 | 28.8 | 111 |
| Net margin | 0.79% | 4.31% | 164 |
| Return on equity | 106.43% | 5.47% | 185 |
| Dividend yield (payers) | 1.01% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
COR price chart
Powered by TradingViewWhat does Cencora, Inc. do?
Cencora, Inc. is a leading global pharmaceutical solutions organization that distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies, and equipment to healthcare providers worldwide. It serves acute care hospitals, health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, nursing and assisted living centers, as well as long-term care, workers' compensation, and specialty drug patients. The company provides drug distribution, consulting services related to medical business operations, patient services, and innovative partnerships with manufacturers, providers, and pharmacies to enhance product access and efficiency throughout the healthcare supply chain. Cencora offers industry-leading solutions for human health and animal health, accelerating better health outcomes from concept to delivery with global support and local expertise in more than 50 countries. Its operations include logistics, warehousing, and support for biopharma breakthroughs, enabling life-changing therapies to reach patients effectively. Headquartered in Conshohocken, Pennsylvania, Cencora plays a vital role in transforming healthcare delivery and fostering healthier futures for people and animals.